Search

Your search keyword '"Ceresoli, Giovanni Luca"' showing total 312 results
Start Over Author "Ceresoli, Giovanni Luca"
312 results on '"Ceresoli, Giovanni Luca"'

1. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

Author

Pala, Laura, Pagan, Eleonora, Sala, Isabella, Oriecuia, Chiara, Oliari, Matteo, De Pas, Tommaso, Specchia, Claudia, Cocorocchio, Emilia, Zattarin, Emma, Rossi, Giovanna, Catania, Chiara, Ceresoli, Giovanni Luca, Laszlo, Daniele, Canzian, Jacopo, Valenzi, Elena, Viale, Giuseppe, Gelber, Richard D., Mantovani, Alberto, Bagnardi, Vincenzo, and Conforti, Fabio

Published
2024
Full Text
View/download PDF

2. Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach

Author

Ceresoli, Giovanni Luca, Rossi, Giulio, Agustoni, Francesco, Bonomi, Lucia, Borghetti, Paolo, Bulotta, Alessandra, Casartelli, Clelia, Cerea, Giulio, Colonese, Francesca, del Signore, Ester, Finocchiaro, Giovanna, Gianoncelli, Letizia, Grisanti, Salvatore, Maiolani, Martina, Pagni, Fabio, Proto, Claudia, Rijavec, Erika, Vittimberga, Isabella, Arcangeli, Stefano, and Filippi, Andrea Riccardo

Published
2024
Full Text
View/download PDF

3. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Author

Chu, Quincy, Perrone, Francesco, Greillier, Laurent, Tu, Wei, Piccirillo, Maria Carmela, Grosso, Federica, Lo Russo, Giuseppe, Florescu, Marie, Mencoboni, Manlio, Morabito, Alessandro, Cecere, Fabiana Letizia, Ceresoli, Giovanni Luca, Dawe, David E, Zucali, Paolo Andrea, Pagano, Maria, Goffin, John R, Sanchez, Myriam Locatelli, Gridelli, Cesare, Zalcman, Gerard, Quantin, Xavier, Westeel, Virginie, Gargiulo, Piera, Delfanti, Sara, Tu, Dongsheng, Lee, Christopher W, Leighl, Natasha, Sederias, Joana, Brown-Walker, Pamela, Luo, Yiwen, Lantuejoul, Sylvie, Tsao, Ming-Sound, Scherpereel, Arnaud, Bradbury, Penelope, Laurie, Scott A, and Seymour, Lesley

Published
2023
Full Text
View/download PDF

4. Diagnostic Applications of Nuclear Medicine: Prostatic Cancer

Author

Evangelista, Laura, Ceresoli, Giovanni Luca, Setti, Lucia, Garbaccio, Viviana, Olivari, Laura, Bonacina, Manuela, Sauta, Maria Grazia, Ciocia, Gianluigi, Vavassori, Vittorio, Villa, Elisa, Meroni, Roberta, Bombardieri, Emilio, Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor

Published
2022
Full Text
View/download PDF

5. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

Author

Procopio, Giuseppe, Chiuri, Vincenzo, Mantini, Giovanna, Roberto Bordonaro, Roberto Maisano., Cinieri, Saverio, Rossetti, Sabrina, De Placido, Sabino, Airoldi, Mario, Galli, Luca, Gasparro, Donatello, Ludovico, Giuseppe Mario, Guglielmini, Pamela Francesca, Santini, Daniele, Naglieri, Emanuele, Fagnani, Daniele, Aglietta, Massimo, Livi, Lorenzo, Schips, Luigi, Passalacqua, Rodolfo, Fiore, Michele, D'Angelillo, Rolando Maria, Ceresoli, Giovanni Luca, Magrini, Stefano, Rondonotti, David, Mirone, Vincenzo, Ferriero, Maria Consiglia, Sciarra, Alessandro, Acquati, Mirko, Boccardo, Francesco, Scagliotti, Giorgio Vittorio, Mencoboni, Manlio, De Giorgi, Ugo, Micheletti, Gennaro, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Soto Parra, Hector Josè, Battaglia, Michele, Uricchio, Francesco, Bernardo, Antonio, De Lisa, Antonello, Carrieri, Giuseppe, Ardizzoia, Antonio, Aieta, Michele, Pisconti, Salvatore, Marchetti, Paolo, Paiar, Fabiola, Procopio, G., Chiuri, V.E., Giordano, M., Alitto, A.R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., De Placido, S., Airoldi, M., Galli, L., Gasparro, D., Ludovico, G.M., Guglielmini, P.F., Carella, C., Nova, P., Aglietta, M., Schips, L., Beccaglia, P., Sciarra, A., Livi, L., and Santini, D.

Published
2022
Full Text
View/download PDF

6. Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses.

Author

Ghirardelli, Paolo, Costantino, Gianluca, Franceschini, Davide, Villa, Elisa, Guaineri, Annamaria, Scorsetti, Marta, Vavassori, Vittorio, and Ceresoli, Giovanni Luca

Abstract

There is growing evidence of a role of stereotactic body radiation therapy (SBRT) in the treatment of patients with oligoprogressive pleural mesothelioma (PM). The objective of this study was to investigate the optimal radiation therapy doses and schedules in this setting. The records of patients treated with SBRT (>5 Gy per fraction) for oligoprogression of PM at 2 institutions from June 2014 to September 2022 were reviewed. Patients were divided into 2 groups: "intermediate-dose" SBRT (i-SBRT; total dose, 30-36 Gy in 5-6 fractions) and "high-dose" SBRT (h-SBRT; total dose, 45-50 Gy in 4-8 fractions). The comparison between the 2 groups in terms of local control (LC) and toxicity was the primary endpoint of the study. Overall, 23 patients were treated for 25 pleural lesions. All had received upfront chemotherapy with platinum/pemetrexed. Fifteen patients were treated with i-SBRT and 8 patients with h-SBRT. The median equivalent dose was 40 Gy (range, 40-49.6) in the i-SBRT group and 74.46 Gy (range, 64-88) in the h-SBRT group. Six-month, 1-year, and 2-year LC were 100%, 100%, and 80% in the i-SBRT group and 100%, 100%, and 67% in the h-SBRT group, respectively (p =.94). Only 2 patients (1 for each dose group) had a recurrence in the radiation therapy field, both after experiencing a distant relapse. No severe acute and late toxicities were observed in the i-SBRT group, whereas in the h-SBRT group, 2 patients experienced G2 acute and late thoracic pain and 1 patient experienced G2 acute and G3 chronic thoracic pain. In our experience, SBRT is a safe and effective option for selected patients with oligoprogressive PM. Use of intermediate total doses keeping the dose per fraction high seems to offer an excellent LC, avoiding the risk of severe toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Pinto, Carmine, Zucali, Paolo Andrea, Pagano, Maria, Grosso, Federica, Pasello, Giulia, Garassino, Marina Chiara, Tiseo, Marcello, Soto Parra, Hector, Grossi, Francesco, Cappuzzo, Federico, de Marinis, Filippo, Pedrazzoli, Paolo, Bonomi, Maria, Gianoncelli, Letizia, Perrino, Matteo, Santoro, Armando, Zanelli, Francesca, Bonelli, Candida, Maconi, Antonio, Frega, Stefano, Gervasi, Erika, Boni, Luca, and Ceresoli, Giovanni Luca

Published
2021
Full Text
View/download PDF

11. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Author

Di Noia, Vincenzo, D’Argento, Ettore, Pilotto, Sara, Vita, Emanuele, Ferrara, Miriam Grazia, Damiano, Paola, Ribelli, Marta, Cannella, Antonella, Virtuoso, Antonella, Fattorossi, Andrea, Ceresoli, Giovanni Luca, Milella, Michele, Beretta, Giordano Domenico, Tortora, Giampaolo, and Bria, Emilio

Published
2021
Full Text
View/download PDF

12. Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

Author

Santini, Daniele, Cinieri, Saverio, Gasparro, Donatello, Bordonaro, Roberto, Guglielmini, Pamela Francesca, Chiuri, Vincenzo Emanuele, D'Angelillo, Rolando M, Ceresoli, Giovanni Luca, Fagnani, Daniele, Acquati, Mirko, Mencoboni, Manlio, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Panebianco, Fabiana, Beccaglia, Patrizia, and Procopio, Giuseppe

Published
2021
Full Text
View/download PDF

13. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

Author

Pala, L, Pagan, E, Sala, I, Oriecuia, C, Oliari, M, De Pas, T, Specchia, C, Cocorocchio, E, Zattarin, E, Rossi, G, Catania, C, Ceresoli, G, Laszlo, D, Canzian, J, Valenzi, E, Viale, G, Gelber, R, Mantovani, A, Bagnardi, V, Conforti, F, Pala, Laura, Pagan, Eleonora, Sala, Isabella, Oriecuia, Chiara, Oliari, Matteo, De Pas, Tommaso, Specchia, Claudia, Cocorocchio, Emilia, Zattarin, Emma, Rossi, Giovanna, Catania, Chiara, Ceresoli, Giovanni Luca, Laszlo, Daniele, Canzian, Jacopo, Valenzi, Elena, Viale, Giuseppe, Gelber, Richard D., Mantovani, Alberto, Bagnardi, Vincenzo, Conforti, Fabio, Pala, L, Pagan, E, Sala, I, Oriecuia, C, Oliari, M, De Pas, T, Specchia, C, Cocorocchio, E, Zattarin, E, Rossi, G, Catania, C, Ceresoli, G, Laszlo, D, Canzian, J, Valenzi, E, Viale, G, Gelber, R, Mantovani, A, Bagnardi, V, Conforti, F, Pala, Laura, Pagan, Eleonora, Sala, Isabella, Oriecuia, Chiara, Oliari, Matteo, De Pas, Tommaso, Specchia, Claudia, Cocorocchio, Emilia, Zattarin, Emma, Rossi, Giovanna, Catania, Chiara, Ceresoli, Giovanni Luca, Laszlo, Daniele, Canzian, Jacopo, Valenzi, Elena, Viale, Giuseppe, Gelber, Richard D., Mantovani, Alberto, Bagnardi, Vincenzo, and Conforti, Fabio

Abstract

Background: The outcome of patients with metastatic tumors who discontinued immune checkpoint inhibitors (ICIs) not for progressive disease (PD) has been poorly explored. We performed a meta-analysis of all studies reporting the clinical outcome of patients who discontinued ICIs for reasons other than PD. Methods: We searched PubMed, Embase and Scopus databases, from the inception of each database to December 2023, for clinical trials (randomized or not) and observational studies assessing PD-(L)1 and CTLA-4 inhibitors in patients with metastatic solid tumors who discontinued treatment for reasons other than PD. Each study had to provide swimmer plots or Kaplan–Meier survival curves enabling the reconstruction of individual patient-level data on progression-free survival (PFS) following the discontinuation of immunotherapy. The primary endpoint was PFS from the date of treatment discontinuation overall and according to tumor histotype, type of treatment and reason of discontinuation. The Combersure's method was used to estimate meta-analytical non-parametric summary survival curves assuming random effects at study level. Findings: Thirty-six studies (2180 patients) were included. The pooled median PFS (mPFS) was 24.7 months (95% CI, 18.8–30.6) and the PFS-rate at 12, 24, and 36 months was respectively 69.8% (95% CI, 63.1–77.3), 51.0% (95% CI, 43.4–59.8) and 34.0% (95% CI, 27.0–42.9). Univariable analysis showed that the mPFS was significantly longer for patients with melanoma (43.0 months), as compared with non-small cell lung cancer (NSCLC, 13.5 months) and renal cell carcinoma (RCC, 10.0 months; between-strata comparison test p-value < 0.001); for patients treated with anti-PD-(L)1 + anti-CTLA-4 as compared with anti-PD-(L)1 monotherapy (44.6 versus 19.9 months; p-value < 0.001), and in NSCLC when the reason of treatment discontinuation was elective as compared with toxicity onset (19.6 versus 4.8 months; p-value = 0.003). The multivariable analysis confirme

Published
2024

14. Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach

Author

Ceresoli, G, Rossi, G, Agustoni, F, Bonomi, L, Borghetti, P, Bulotta, A, Casartelli, C, Cerea, G, Colonese, F, del Signore, E, Finocchiaro, G, Gianoncelli, L, Grisanti, S, Maiolani, M, Pagni, F, Proto, C, Rijavec, E, Vittimberga, I, Arcangeli, S, Filippi, A, Ceresoli, Giovanni Luca, Rossi, Giulio, Agustoni, Francesco, Bonomi, Lucia, Borghetti, Paolo, Bulotta, Alessandra, Casartelli, Clelia, Cerea, Giulio, Colonese, Francesca, del Signore, Ester, Finocchiaro, Giovanna, Gianoncelli, Letizia, Grisanti, Salvatore, Maiolani, Martina, Pagni, Fabio, Proto, Claudia, Rijavec, Erika, Vittimberga, Isabella, Arcangeli, Stefano, Filippi, Andrea Riccardo, Ceresoli, G, Rossi, G, Agustoni, F, Bonomi, L, Borghetti, P, Bulotta, A, Casartelli, C, Cerea, G, Colonese, F, del Signore, E, Finocchiaro, G, Gianoncelli, L, Grisanti, S, Maiolani, M, Pagni, F, Proto, C, Rijavec, E, Vittimberga, I, Arcangeli, S, Filippi, A, Ceresoli, Giovanni Luca, Rossi, Giulio, Agustoni, Francesco, Bonomi, Lucia, Borghetti, Paolo, Bulotta, Alessandra, Casartelli, Clelia, Cerea, Giulio, Colonese, Francesca, del Signore, Ester, Finocchiaro, Giovanna, Gianoncelli, Letizia, Grisanti, Salvatore, Maiolani, Martina, Pagni, Fabio, Proto, Claudia, Rijavec, Erika, Vittimberga, Isabella, Arcangeli, Stefano, and Filippi, Andrea Riccardo

Abstract

Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.

Published
2024

16. Bone Metastases in Prostate Cancer

Author

Bonomi, Maria, Cerchiaro, Eleonora, Villa, Elisa, Setti, Lucia Rebecca, Gianoncelli, Letizia, Micheli, Emanuele, Ceresoli, Giovanni Luca, Bombardieri, Emilio, editor, Seregni, Ettore, editor, Evangelista, Laura, editor, Chiesa, Carlo, editor, and Chiti, Arturo, editor

Published
2018
Full Text
View/download PDF

18. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.

Author

Rossi, Giulio, Righi, Luisella, Barbisan, Francesca, Tiseo, Marcello, Spagnolo, Paolo, Grosso, Federica, Pisapia, Pasquale, Malapelle, Umberto, Sculco, Marika, Dianzani, Irma, Abate-Daga, Laura, Davolio, Maria Cristina, Ceresoli, Giovanni Luca, Galetta, Domenico, Pasello, Giulia, Novello, Silvia, and Bironzo, Paolo

Subjects
MESOTHELIOMA, DRUG approval, PATHOLOGY, DIAGNOSIS, PLEURA cancer, PLEURA diseases, MEDICAL screening
Abstract

The pathologic diagnosis of pleural mesothelioma is generally based on international guidelines, but no compulsory points based on different drugs approvals in different European countries are required to be reported. According to the last (2021) edition of the World Health Organization classification of pleural tumors, the nuclear grade of epithelioid-type mesothelioma should be always inserted in the pathologic report, while the presence of BRCA-associated protein-1 (BAP1) (clone C4) loss and a statement on the presence of the sarcomatoid/nonepithelioid component are fundamental for both a screening of patients with suspected BAP1 tumor predisposition syndrome and the eligibility to perform first-line immunotherapy at least in some countries. Several Italian experts on pleural mesothelioma who are deeply involved in national scientific societies or dedicated working groups supported by patient associations agreed that the pathology report of mesothelioma of the pleura should always include the nuclear grade in the epithelioid histology, which is an overt statement on the presence of sarcomatoid components (at least 1%, in agreement with the last classification of pleural mesothelioma) and the presence of BAP1 loss (BAP1-deficient mesothelioma) or not (BAP1-retained mesothelioma) in order to screen patients possibly harboring BAP1 tumor predisposition syndrome. This review aims to summarize the most recent data on these three important elements to provide evidence regarding the possible precision needs for mesothelioma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Combinations of Hormonal Therapy and Chemotherapy

Author

Ceresoli, Giovanni Luca, Bonomi, Maria, Sauta, Maria Grazia, Zanardi, Elisa, Boccardo, Francesco, Bertoldo, Francesco, editor, Boccardo, Francesco, editor, Bombardieri, Emilio, editor, Evangelista, Laura, editor, and Valdagni, Riccardo, editor

Published
2017
Full Text
View/download PDF

20. Chemotherapy

Author

Ceresoli, Giovanni Luca, Bonomi, Maria, Sauta, Maria Grazia, Bertoldo, Francesco, editor, Boccardo, Francesco, editor, Bombardieri, Emilio, editor, Evangelista, Laura, editor, and Valdagni, Riccardo, editor

Published
2017
Full Text
View/download PDF

23. Data from Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program

Author

Baryshnikova, Ekaterina, primary, Destro, Annarita, primary, Infante, Maurizio Valentino, primary, Cavuto, Silvio, primary, Cariboni, Umberto, primary, Alloisio, Marco, primary, Ceresoli, Giovanni Luca, primary, Lutman, Romano, primary, Brambilla, Giorgio, primary, Chiesa, Giuseppe, primary, Ravasi, Gianni, primary, and Roncalli, Massimo, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables S1-S3 from Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program

Author

Baryshnikova, Ekaterina, primary, Destro, Annarita, primary, Infante, Maurizio Valentino, primary, Cavuto, Silvio, primary, Cariboni, Umberto, primary, Alloisio, Marco, primary, Ceresoli, Giovanni Luca, primary, Lutman, Romano, primary, Brambilla, Giorgio, primary, Chiesa, Giuseppe, primary, Ravasi, Gianni, primary, and Roncalli, Massimo, primary

Published
2023
Full Text
View/download PDF

26. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Author

Ignatius Ou, SaiHong, Planchard, David, Park, Keunchil, Schuler, Martin, Yang, James, Chand, Vikram, Rohr, Klaus, Bagnes, Claudia, Martin, Claudio Marcelo, Recondo, Gonzalo, Zarba, Juan Jose, Blajman, Cesar, Richardet, Martín, McLachlan, Sue-Anne, Parente, Phillip, Underhill, Craig, Crombie, Catherine, Mainwaring, Paul, Greil, Richard, Humblet, Yves, Bustin, Frédérique, Carestia, Luciano, Galdermans, Danny, Lambrechts, Marc, Delval, Laetitia, Vercauter, Piet, Zhou, Caicun, Wang, Jin, Huang, Cheng, Lin, Xiaoyan, Wu, Yilong, Liu, Xiaoqing, Cheng, Ying, Qin, Shukui, Feng, Jifeng, Huang, Jianjin, Zhang, Yiping, Lu, Shun, Zereu, Manuela, Garicochea, Bernardo, Zadra, Cyntia Albuquerque, Riska, Henrik, Alanko, Tuomo, Cadranel, Jacques, Chouaid, Christos, Zalcman, Gérard, Sibilot, Denis Moro, Perol, Maurice, Bennouna, Jaafar, Fournel, Pierre, Gervais, Radj, Rotarski, Maciej, Coudert, Bruno, Thomas, Michael, Wehler, Thomas, Faehling, Martin, Keilholz, Ulrich, Laack, Eckart, von Pawel, Joachim, Huber, Rudolf, Dickgreber, Nicolas, Wiewrodt, Rainer, Mark, Zsuzsanna, Tehenes, Sandor, Strausz, Janos, Sarosi, Veronika, Prabhash, Kumar, Jain, Minish, Venkatesan, Srinivasan, Sharma, Lalit, Dadhich, Hemant, Nagarkar, Rajnish Vasant, Onn, Amir, Gottfried, Maya, Stemmer, Solomon, Migliorino, Maria Rita, Grossi, Francesco, Bidoli, Paolo, Bearz, Alessandra, Gridelli, Cesare, Milandri, Carlo, Platania, Marco, Ceresoli, Giovanni Luca, Cruciani, Giorgio, Delgado, Francisco Gutierrez, Gonzalez Perez, José Luis, Luna, Gabriela Alvarado, Baca, Othon Padilla, Aerts, J.G.J.V., Stigt, J.A., Dingemans, A.M.C., Herder, G.J.M., Gans, S.J.M., Salas Sánchez, Jorge Fernando, Alvarez Barreda, Renzo Luzgardo, Pantigoso, Wilbert Rodriguez, Palomino, Osbert Luis Mejia, Jaskiewicz, Piotr, Kazarnowicz, Andrzej, Serwatowski, Piotr, Szczesna, Aleksandra, Jassem, Jacek, Lubennikov, Vladimir, Karaseva, Nina, Orlov, Sergey, Ragulin, Yuri, Garrido, Pilar, González Larriba, José Luis, Camps, Carlos, Campelo, Rosario García, Lianes, Pilar, Cobo, Manuel, Felip, Enriqueta, Kim, Dong-Wan, Kim, Sang-We, Kim, Joo-Hang, Han, Ji-Youn, Kim, Young-Chul, Yang, Chih-Hsin, Hsia, Te-Chun, Chen, Yuh-Min, Tsai, Ying-Huang, Chang, Gee-Chen, Tsao, Thomas Chang-Yao, Su, Wu-Chou, Huang, Ming-Shyan, Ho, Ching-Liang, Hsieh, Ruey-Kuen, Vinnyk, Yuriy, Popovych, Oleksandr, Ponomarova, Olga, Bondarenko, Igor, Polishchuk, Iryna, Shah, Riyaz, Mitra, Sanka, Popat, Sanjaykumar, Spicer, James, Toy, Elizabeth, Talbot, Toby, Brown, Emma, Upadhyay, Sunil, Summers, Yvonne, Gurtler, Jayne, Meza, Luis, Thropay, John, Schuler, M., Yang, J.C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V.K., and Planchard, D.

Published
2016
Full Text
View/download PDF

29. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study

Author

Mannarino, Laura, primary, Paracchini, Lara, additional, Pezzuto, Federica, additional, Olteanu, Gheorghe Emilian, additional, Moracci, Laura, additional, Vedovelli, Luca, additional, De Simone, Irene, additional, Bosetti, Cristina, additional, Lupi, Monica, additional, Amodeo, Rosy, additional, Inglesi, Alessia, additional, Callari, Maurizio, additional, Penpa, Serena, additional, Libener, Roberta, additional, Delfanti, Sara, additional, De Angelis, Antonina, additional, Muzio, Alberto, additional, Zucali, Paolo Andrea, additional, Allavena, Paola, additional, Ceresoli, Giovanni Luca, additional, Marchini, Sergio, additional, Calabrese, Fiorella, additional, D’Incalci, Maurizio, additional, and Grosso, Federica, additional

Published
2022
Full Text
View/download PDF

30. Chemotherapy

Author

Ceresoli, Giovanni Luca, primary, Bonomi, Maria, additional, and Sauta, Maria Grazia, additional

Published
2016
Full Text
View/download PDF

33. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Author

Schuler, M., Yang, J. C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V. K., Planchard, D., Ignatius Ou, Sai Hong, Planchard, David, Park, Keunchil, Schuler, Martin, Yang, James, Chand, Vikram, Rohr, Klaus, Bagnes, Claudia, Martin, Claudio Marcelo, Recondo, Gonzalo, Zarba, Juan Jose, Blajman, Cesar, Richardet, Martín, McLachlan, Sue-Anne, Parente, Phillip, Underhill, Craig, Crombie, Catherine, Mainwaring, Paul, Greil, Richard, Humblet, Yves, Bustin, Frédérique, Carestia, Luciano, Galdermans, Danny, Lambrechts, Marc, Delval, Laetitia, Vercauter, Piet, Zhou, Caicun, Wang, Jin, Huang, Cheng, Lin, Xiaoyan, Wu, Yilong, Liu, Xiaoqing, Cheng, Ying, Qin, Shukui, Feng, Jifeng, Huang, Jianjin, Zhang, Yiping, Lu, Shun, Zereu, Manuela, Garicochea, Bernardo, Zadra, Cyntia Albuquerque, Riska, Henrik, Alanko, Tuomo, Cadranel, Jacques, Chouaid, Christos, Zalcman, Gérard, Sibilot, Denis Moro, Perol, Maurice, Planchard, David, Bennouna, Jaafar, Fournel, Pierre, Gervais, Radj, Rotarski, Maciej, Coudert, Bruno, Schuler, Martin, Thomas, Michael, Wehler, Thomas, Faehling, Martin, Keilholz, Ulrich, Laack, Eckart, von Pawel, Joachim, Huber, Rudolf, Dickgreber, Nicolas, Wiewrodt, Rainer, Mark, Zsuzsanna, Tehenes, Sandor, Strausz, Janos, Sarosi, Veronika, Prabhash, Kumar, Jain, Minish, Venkatesan, Srinivasan, Sharma, Lalit, Dadhich, Hemant, Nagarkar, Rajnish Vasant, Onn, Amir, Gottfried, Maya, Stemmer, Solomon, Migliorino, Maria Rita, Grossi, Francesco, Bidoli, Paolo, Bearz, Alessandra, Gridelli, Cesare, Milandri, Carlo, Platania, Marco, Ceresoli, Giovanni Luca, Cruciani, Giorgio, Delgado, Francisco Gutierrez, Gonzalez Perez, José Luis, Luna, Gabriela Alvarado, Baca, Othon Padilla, Aerts, J.G.J.V., Stigt, J.A., Dingemans, A.M.C., Herder, G.J.M., Gans, S. J. M., Salas Sánchez, Jorge Fernando, Alvarez Barreda, Renzo Luzgardo, Pantigoso, Wilbert Rodriguez, Palomino, Osbert Luis Mejia, Jaskiewicz, Piotr, Kazarnowicz, Andrzej, Serwatowski, Piotr, Szczesna, Aleksandra, Jassem, Jacek, Lubennikov, Vladimir, Karaseva, Nina, Orlov, Sergey, Ragulin, Yuri, Garrido, Pilar, González Larriba, José Luis, Camps, Carlos, Campelo, Rosario García, Lianes, Pilar, Cobo, Manuel, Felip, Enriqueta, Kim, Dong-Wan, Kim, Sang-We, Park, Keunchil, Kim, Joo-Hang, Han, Ji-Youn, Kim, Young-Chul, Yang, Chih-Hsin, Hsia, Te-Chun, Chen, Yuh-Min, Tsai, Ying-Huang, Chang, Gee-Chen, Tsao, Thomas Chang-Yao, Su, Wu-Chou, Huang, Ming-Shyan, Ho, Ching-Liang, Hsieh, Ruey-Kuen, Vinnyk, Yuriy, Popovych, Oleksandr, Ponomarova, Olga, Bondarenko, Igor, Polishchuk, Iryna, Shah, Riyaz, Mitra, Sanka, Popat, Sanjaykumar, Spicer, James, Toy, Elizabeth, Popat, Sanjaykumar, Talbot, Toby, Brown, Emma, Upadhyay, Sunil, Summers, Yvonne, Gurtler, Jayne, Meza, Luis, and Thropay, John

Published
2016
Full Text
View/download PDF

34. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Author

Bracarda, S., Iacovelli, R., Boni, L., Rizzo, M., Derosa, L., Rossi, M., Galli, L., Procopio, G., Sisani, M., Longo, F., Santoni, M., Morelli, F., Di Lorenzo, G., Altavilla, A., Porta, C., Camerini, A., Escudier, B., Martignetti, Angelo, Ricotta, Riccardo, Gasparro, Donatello, Sabbatini, Roberto, Ceresoli, Giovanni Luca, Mosca, Alessandra, Santini, Daniele, Caserta, Claudia, Cavanna, Luigi, Massari, Francesco, Sava, Teodoro, Boni, Corrado, Verzoni, Elena, Cartenì, Giacomo, and Hamzaj, Alketa

Published
2015
Full Text
View/download PDF

36. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment

Author

Pezzuto, Federica, primary, Lunardi, Francesca, additional, Vedovelli, Luca, additional, Fortarezza, Francesco, additional, Urso, Loredana, additional, Grosso, Federica, additional, Ceresoli, Giovanni Luca, additional, Kern, Izidor, additional, Vlacic, Gregor, additional, Faccioli, Eleonora, additional, Schiavon, Marco, additional, Gregori, Dario, additional, Rea, Federico, additional, Pasello, Giulia, additional, and Calabrese, Fiorella, additional

Published
2021
Full Text
View/download PDF

40. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Author

Di Noia, Vincenzo, primary, D’Argento, Ettore, additional, Pilotto, Sara, additional, Vita, Emanuele, additional, Ferrara, Miriam Grazia, additional, Damiano, Paola, additional, Ribelli, Marta, additional, Cannella, Antonella, additional, Virtuoso, Antonella, additional, Fattorossi, Andrea, additional, Ceresoli, Giovanni Luca, additional, Milella, Michele, additional, Beretta, Giordano Domenico, additional, Tortora, Giampaolo, additional, and Bria, Emilio, additional

Published
2020
Full Text
View/download PDF

42. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study.

Author

Di Noia, Vincenzo, primary, D'Argento, Ettore, additional, Pilotto, Sara, additional, Carbone, Carmine, additional, Vita, Emanuele, additional, Ceresoli, Giovanni Luca, additional, Beretta, Giordano D., additional, Tortora, Giampaolo, additional, and Bria, Emilio, additional

Published
2020
Full Text
View/download PDF

43. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.

Author

Pagano, Maria, primary, Ceresoli, Giovanni Luca, additional, Zucali, Paolo Andrea, additional, Pasello, Giulia, additional, Garassino, Marina Chiara, additional, Grosso, Federica, additional, Tiseo, Marcello, additional, Soto Parra, Hector J., additional, Zanelli, Francesca, additional, Cappuzzo, Federico, additional, Grossi, Francesco, additional, de Marinis, Filippo, additional, Pedrazzoli, Paolo, additional, Gnoni, Roberta, additional, Bonelli, Candida, additional, Berselli, Annalisa, additional, Boni, Luca, additional, Normanno, Nicola, additional, and Pinto, Carmine, additional

Published
2020
Full Text
View/download PDF

44. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Author

Herbst, Roy S., primary, Garon, Edward B., additional, Kim, Dong-Wan, additional, Cho, Byoung Chul, additional, Perez-Gracia, Jose L., additional, Han, Ji-Youn, additional, Arvis, Catherine Dubos, additional, Majem, Margarita, additional, Forster, Martin D., additional, Monnet, Isabelle, additional, Novello, Silvia, additional, Szalai, Zsuzsanna, additional, Gubens, Matthew A., additional, Su, Wu-Chou, additional, Ceresoli, Giovanni Luca, additional, Samkari, Ayman, additional, Jensen, Erin H., additional, Lubiniecki, Gregory M., additional, and Baas, Paul, additional

Published
2020
Full Text
View/download PDF

45. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

Author

Baldini, Editta, primary, Lunghi, Alice, additional, Cortesi, Enrico, additional, Turci, Daniele, additional, Signorelli, Diego, additional, Stati, Valeria, additional, Melotti, Barbara, additional, Ricciuti, Biagio, additional, Frassoldati, Antonio, additional, Romano, Giampiero, additional, Ceresoli, Giovanni Luca, additional, Illiano, Alfonso, additional, Verderame, Francesco, additional, Fasola, Gianpiero, additional, Ricevuto, Enrico, additional, Marchetti, Paolo, additional, Pinto, Carmine, additional, Cartenì, Giacomo, additional, Scotti, Vieri, additional, Tibaldi, Carmelo, additional, Fioretto, Luisa, additional, and Giannarelli, Diana, additional

Published
2020
Full Text
View/download PDF

46. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

Author

Reale, Maria Lucia, primary, Chiari, Rita, additional, Tiseo, Marcello, additional, Vitiello, Fabiana, additional, Barbieri, Fausto, additional, Cortinovis, Diego, additional, Ceresoli, Giovanni Luca, additional, Finocchiaro, Giovanna, additional, Romano, Gianpiero Diego, additional, Piovano, Pier Luigi, additional, Del Conte, Alessandro, additional, Borra, Gloria, additional, Verderame, Francesco, additional, Scotti, Vieri, additional, Nonnis, Daniela, additional, Galetta, Domenico, additional, Sergi, Concetta, additional, Migliorino, Maria Rita, additional, Tonini, Giuseppe, additional, Cecere, Fabiana, additional, Berardi, Rossana, additional, Pino, Maria Simona, additional, Martelli, Olga, additional, Gelibter, Alain, additional, Carta, Annamaria, additional, Vattemi, Emanuela, additional, Pagano, Maria, additional, Zullo, Alessandro, additional, Ferrari, Silvia, additional, Rossi, Antonio, additional, and Novello, Silvia, additional

Published
2020
Full Text
View/download PDF

49. ROLE OF COMPUTED TOMOGRAPHY AND [18F] FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IMAGE FUSION IN CONFORMAL RADIOTHERAPY OF NON-SMALL CELL LUNG CANCER: A COMPARISON WITH STANDARD TECHNIQUES WITH AND WITHOUT ELECTIVE NODAL IRRADIATION

Author

Ceresoli, Giovanni Luca, Cattaneo, Giovanni Mauro, Castellone, Pietro, Rizzo, Giovanna, Landoni, Claudio, Gregorc, Vanesa, Calandrino, Riccardo, Villa, Eugenio, Messa, Cristina, Santoro, Armando, and Fazio, Ferruccio

Published
2007
Full Text
View/download PDF

50. Optimizing Anti-EGFR Strategies in Cancer Treatment

Author

Toschi, Luca, Finocchiaro, Giovanna, Garassino, Isabella, De Vincenzo, Fabio, Campagnoli, Elisabetta, Ceresoli, Giovanni Luca, Cavina, Raffaele, Zucali, Paolo Andrea, Santoro, Armando, and Cappuzzo, Federico

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results